Compare UNCY & OCAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNCY | OCAC |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 156.2M |
| IPO Year | 2021 | 2022 |
| Metric | UNCY | OCAC |
|---|---|---|
| Price | $4.06 | $9.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $28.40 | N/A |
| AVG Volume (30 Days) | ★ 802.1K | 27.6K |
| Earning Date | 11-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10,812.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $9.86 |
| 52 Week High | $8.74 | $10.05 |
| Indicator | UNCY | OCAC |
|---|---|---|
| Relative Strength Index (RSI) | 29.66 | 71.41 |
| Support Level | $3.93 | $9.94 |
| Resistance Level | $5.86 | N/A |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 3.22 | 45.45 |
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Ocean Capital Acquisition Corp is a blank check company.